Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Hogarty

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Cell Research|April 2, 2010
Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival proteinMichael D Hogarty
Cancer Letters|July 26, 2003
The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplificationMichael D Hogarty
Journal of the National Cancer Institute|April 26, 2015
Expanding MYCN's reach in oncogenic transcriptionMichael D Hogarty
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 2, 2011
IL-17A in LCH: systemic biomarker, local factor, or none of the above?Michael D Hogarty
Cancer Letters|June 2, 2005
Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastomaKelly C Goldsmith, Michael D Hogarty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastomaNicholas F Evageliou, Michael D Hogarty
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2009
Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancerKelly C Goldsmith, Michael D Hogarty
Cancer Cell|February 21, 2012
PI3King on MYCN to improve neuroblastoma therapeuticsMichael D Hogarty, John M Maris
Pediatric Blood & Cancer|April 11, 2020
The ASPHO 2020 distinguished career award goes to Dr Garrett M. BrodeurMichael D Hogarty, Stephen P Hunger
Medical Sciences (Basel, Switzerland)|May 26, 2018
Myc, Oncogenic Protein Translation, and the Role of PolyaminesAndrea T Flynn, Michael D Hogarty
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Cell Research|April 2, 2010
Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival proteinMichael D Hogarty
Cancer Letters|July 26, 2003
The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplificationMichael D Hogarty
Journal of the National Cancer Institute|April 26, 2015
Expanding MYCN's reach in oncogenic transcriptionMichael D Hogarty
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 2, 2011
IL-17A in LCH: systemic biomarker, local factor, or none of the above?Michael D Hogarty
Cancer Letters|June 2, 2005
Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastomaKelly C Goldsmith, Michael D Hogarty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastomaNicholas F Evageliou, Michael D Hogarty
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2009
Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancerKelly C Goldsmith, Michael D Hogarty
Cancer Cell|February 21, 2012
PI3King on MYCN to improve neuroblastoma therapeuticsMichael D Hogarty, John M Maris
Pediatric Blood & Cancer|April 11, 2020
The ASPHO 2020 distinguished career award goes to Dr Garrett M. BrodeurMichael D Hogarty, Stephen P Hunger
Medical Sciences (Basel, Switzerland)|May 26, 2018
Myc, Oncogenic Protein Translation, and the Role of PolyaminesAndrea T Flynn, Michael D Hogarty
Pageof 11